Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Insider: T-Mobile, Intel among weeks notable insider trades » 13:04
07/06/20
07/06
13:04
07/06/20
13:04
CLR

Continental Resources

$17.28 /

-1.02 (-5.57%)

, TMUS

T-Mobile

$106.43 /

+0.44 (+0.42%)

, BLFS

BioLife Solutions

$18.38 /

+0.38 (+2.11%)

, LQDA

Liquidia Technologies

$7.95 /

+0.17 (+2.19%)

, EVLO

Evelo Biosciences

$4.55 /

-0.48 (-9.54%)

, SRT

StarTek

$5.17 /

+0.02 (+0.39%)

, MRVL

Marvell

$36.44 /

+1.44 (+4.11%)

, APPN

Appian

$50.59 /

-2.09 (-3.97%)

, AVGO

Broadcom

$319.58 /

+4.25 (+1.35%)

, CARG

CarGurus

$26.49 /

+0.21 (+0.80%)

, INTC

Intel

$59.33 /

+0.22 (+0.37%)

Welcome to "Fly Insider,"…

Open Full Text

ShowHide Related Items >><<
TMUS T-Mobile
$106.43 /

+0.44 (+0.42%)

SRT StarTek
$5.17 /

+0.02 (+0.39%)

MRVL Marvell
$36.44 /

+1.44 (+4.11%)

LQDA Liquidia Technologies
$7.95 /

+0.17 (+2.19%)

INTC Intel
$59.33 /

+0.22 (+0.37%)

EVLO Evelo Biosciences
$4.55 /

-0.48 (-9.54%)

CLR Continental Resources
$17.28 /

-1.02 (-5.57%)

CARG CarGurus
$26.49 /

+0.21 (+0.80%)

BLFS BioLife Solutions
$18.38 /

+0.38 (+2.11%)

AVGO Broadcom
$319.58 /

+4.25 (+1.35%)

APPN Appian
$50.59 /

-2.09 (-3.97%)

CLR Continental Resources
$17.28 /

-1.02 (-5.57%)

06/23/20 Imperial Capital
Continental Resources price target raised to $18 from $14 at Imperial Capital
06/19/20 Mizuho
Continental Resources price target raised to $15 from $8 at Mizuho
06/09/20 MKM Partners
Continental Resources downgraded to Neutral from Buy at MKM Partners
06/09/20 MKM Partners
Continental Resources downgraded to Neutral from Buy at MKM Partners
TMUS T-Mobile
$106.43 /

+0.44 (+0.42%)

06/12/20 Deutsche Bank
Deutsche Bank still believes Dish acquisition of Boost will close
06/11/20 Wells Fargo
T-Mobile price target raised to $120 from $110 at Wells Fargo
06/09/20
Fly Intel: Top five analyst downgrades
06/09/20 Guggenheim
T-Mobile downgraded to Neutral on valuation at Guggenheim
BLFS BioLife Solutions
$18.38 /

+0.38 (+2.11%)

07/02/20 Lake Street
BioLife Solutions supplementing cash position 'makes sense,' says Lake Street
05/15/20 Stephens
BioLife Solutions price target raised to $24 after 'strong' Q1 beat at Stephens
03/23/20 H.C. Wainwright
BioLife Solutions price target lowered to $17 from $26 at H.C. Wainwright
02/24/20 Lake Street
BioLife Solutions initiated with a Buy at Lake Street
LQDA Liquidia Technologies
$7.95 /

+0.17 (+2.19%)

04/08/20 Wedbush
Liquidia Technologies price target raised to $41 from $37 at Wedbush
01/27/20 Wedbush
Liquidia NDA acceptance reduces regulatory risk, says Wedbush
12/26/19 Wedbush
Liquidia Technologies price target lowered to $37 from $50 at Wedbush
EVLO Evelo Biosciences
$4.55 /

-0.48 (-9.54%)

07/02/20 BMO Capital
Evelo Biosciences price target lowered to $17 from $21 at BMO Capital
05/21/20 Morgan Stanley
Morgan Stanley downgrades Evelo to Equal Weight after AD discontinuation
05/21/20 Morgan Stanley
Evelo Biosciences downgraded to Equal Weight from Overweight at Morgan Stanley
05/12/20 Jefferies
Evelo Biosciences downgraded to Hold from Buy at Jefferies
SRT StarTek
$5.17 /

+0.02 (+0.39%)

06/11/20 Lake Street
StarTek price target lowered to $10 from $12 at Lake Street
06/11/20 B. Riley FBR
StarTek selloff brings attractive entry point, says B. Riley FBR
04/08/20 B. Riley FBR
StarTek price target lowered to $6 from $10.50 at B. Riley FBR
03/13/20 Lake Street
StarTek valuation compelling after strong Q4, says Lake Street
MRVL Marvell
$36.44 /

+1.44 (+4.11%)

07/06/20 Rosenblatt
Samsung on track to replace Nokia as 5G RAN supplier at Verizon, says Rosenblatt
05/29/20 Susquehanna
Marvell delivered results beyond expectations, says Susquehanna
05/29/20 JPMorgan
Marvell price target raised to $36 from $31 at JPMorgan
05/29/20 Needham
Marvell price target raised to $34 from $28 at Needham
APPN Appian
$50.59 /

-2.09 (-3.97%)

06/29/20 Goldman Sachs
Appian price target raised to $46 from $42 at Goldman Sachs
04/14/20 Morgan Stanley
Appian downgraded to Underweight on near-term challenges at Morgan Stanley
04/14/20 Morgan Stanley
Appian downgraded to Underweight from Equal Weight at Morgan Stanley
02/19/20 Needham
Appian downgraded to Hold from Buy at Needham
AVGO Broadcom
$319.58 /

+4.25 (+1.35%)

07/06/20 Goldman Sachs
Broadcom price target raised to $322 from $286 at Goldman Sachs
06/26/20
Fly Intel: Top five analyst upgrades
06/26/20 Evercore ISI
Evercore upgrades Broadcom to Outperform, sees Apple sales driving upside
06/26/20 Evercore ISI
Broadcom upgraded to Outperform from In Line at Evercore ISI
CARG CarGurus
$26.49 /

+0.21 (+0.80%)

06/18/20 JMP Securities
CarGurus price target raised to $32 from $30 at JMP Securities
05/12/20 DA Davidson
CarGurus price target lowered to $31 from $40 at DA Davidson
05/11/20 RBC Capital
CarGurus price target raised to $25 from $22 at RBC Capital
05/11/20 Citi
CarGurus downgraded to Neutral on short-term risks at Citi
INTC Intel
$59.33 /

+0.22 (+0.37%)

07/06/20
Fly Intel: Top five analyst downgrades
07/06/20 Goldman Sachs
Intel downgraded to Sell from Neutral at Goldman Sachs
06/26/20 KeyBanc
Memory supply remains limited in 2H amid low visibility, says KeyBanc
06/23/20 Oppenheimer
Apple creating 'wide moat' for own ecosystem, says Oppenheimer
TMUS T-Mobile
$106.43 /

+0.44 (+0.42%)

SRT StarTek
$5.17 /

+0.02 (+0.39%)

MRVL Marvell
$36.44 /

+1.44 (+4.11%)

LQDA Liquidia Technologies
$7.95 /

+0.17 (+2.19%)

INTC Intel
$59.33 /

+0.22 (+0.37%)

EVLO Evelo Biosciences
$4.55 /

-0.48 (-9.54%)

CLR Continental Resources
$17.28 /

-1.02 (-5.57%)

CARG CarGurus
$26.49 /

+0.21 (+0.80%)

BLFS BioLife Solutions
$18.38 /

+0.38 (+2.11%)

AVGO Broadcom
$319.58 /

+4.25 (+1.35%)

APPN Appian
$50.59 /

-2.09 (-3.97%)

  • 02
    Jul
  • 30
    Jun
  • 25
    Jun
  • 24
    Jun
  • 29
    May
  • 24
    Dec
  • 05
    Sep
TMUS T-Mobile
$106.43 /

+0.44 (+0.42%)

MRVL Marvell
$36.44 /

+1.44 (+4.11%)

INTC Intel
$59.33 /

+0.22 (+0.37%)

CLR Continental Resources
$17.28 /

-1.02 (-5.57%)

CARG CarGurus
$26.49 /

+0.21 (+0.80%)

AVGO Broadcom
$319.58 /

+4.25 (+1.35%)

TMUS T-Mobile
$106.43 /

+0.44 (+0.42%)

SRT StarTek
$5.17 /

+0.02 (+0.39%)

MRVL Marvell
$36.44 /

+1.44 (+4.11%)

LQDA Liquidia Technologies
$7.95 /

+0.17 (+2.19%)

INTC Intel
$59.33 /

+0.22 (+0.37%)

EVLO Evelo Biosciences
$4.55 /

-0.48 (-9.54%)

CLR Continental Resources
$17.28 /

-1.02 (-5.57%)

CARG CarGurus
$26.49 /

+0.21 (+0.80%)

BLFS BioLife Solutions
$18.38 /

+0.38 (+2.11%)

AVGO Broadcom
$319.58 /

+4.25 (+1.35%)

APPN Appian
$50.59 /

-2.09 (-3.97%)

TMUS T-Mobile
$106.43 /

+0.44 (+0.42%)

MRVL Marvell
$36.44 /

+1.44 (+4.11%)

LQDA Liquidia Technologies
$7.95 /

+0.17 (+2.19%)

INTC Intel
$59.33 /

+0.22 (+0.37%)

CLR Continental Resources
$17.28 /

-1.02 (-5.57%)

AVGO Broadcom
$319.58 /

+4.25 (+1.35%)

APPN Appian
$50.59 /

-2.09 (-3.97%)

INTC Intel
$59.33 /

+0.22 (+0.37%)

On The Fly
Fly Intel: Wall Street's top stories for Tuesday » 17:29
06/30/20
06/30
17:29
06/30/20
17:29
MU

Micron

$51.50 /

+2.38 (+4.85%)

, WFC

Wells Fargo

$25.57 /

-0.13 (-0.51%)

, RDS.A

Royal Dutch Shell

$32.70 /

-0.73 (-2.18%)

, RDS.B

Royal Dutch Shell

$30.54 /

-0.785 (-2.51%)

, LULU

Lululemon

$311.96 /

+18.51 (+6.31%)

, UBER

Uber

$31.07 /

+1.435 (+4.84%)

, EADSY

Airbus

$0.00 /

+ (+0.00%)

, TNDM

TNDM

/

+

, UNH

UnitedHealth

$294.79 /

+5.49 (+1.90%)

, AYI

Acuity Brands

$95.47 /

+6.24 (+6.99%)

, LQDA

Liquidia Technologies

$8.36 /

-2.32 (-21.72%)

, INO

Inovio

$26.88 /

-4.83 (-15.23%)

Stocks gained to close…

Open Full Text

ShowHide Related Items >><<
WFC Wells Fargo
$25.57 /

-0.13 (-0.51%)

UNH UnitedHealth
$294.79 /

+5.49 (+1.90%)

UBER Uber
$31.07 /

+1.435 (+4.84%)

TNDM TNDM
/

+

RDS.B Royal Dutch Shell
$30.54 /

-0.785 (-2.51%)

RDS.A Royal Dutch Shell
$32.70 /

-0.73 (-2.18%)

MU Micron
$51.50 /

+2.38 (+4.85%)

LULU Lululemon
$311.96 /

+18.51 (+6.31%)

LQDA Liquidia Technologies
$8.36 /

-2.32 (-21.72%)

INO Inovio
$26.88 /

-4.83 (-15.23%)

EADSY Airbus
$0.00 /

+ (+0.00%)

AYI Acuity Brands
$95.47 /

+6.24 (+6.99%)

MU Micron
$51.50 /

+2.38 (+4.85%)

06/30/20 RBC Capital
Micron price target raised to $60 from $55 at RBC Capital
06/30/20 Morgan Stanley
Morgan Stanley would add to Micron positions on weakness in coming 'rough patch'
06/30/20 Raymond James
Micron price target raised to $65 from $60 at Raymond James
06/30/20 Mizuho
Micron price target raised to $63 from $60 at Mizuho
WFC Wells Fargo
$25.57 /

-0.13 (-0.51%)

06/30/20 JPMorgan
Wells Fargo needs to cut dividend 'much more' than 25%, says JPMorgan
06/30/20 RBC Capital
Wells Fargo price target lowered to $29 from $35 at RBC Capital
06/26/20 Morgan Stanley
Morgan Stanley sees dividend cuts at Wells Fargo, Capital One after stress tests
06/11/20 JPMorgan
Wells Fargo dividend very likely to be cut, says JPMorgan
RDS.A Royal Dutch Shell
$32.70 /

-0.73 (-2.18%)

06/15/20 UBS
Royal Dutch Shell price target raised to 1,750 GBp from 1,650 GBp at UBS
05/13/20 Redburn
Royal Dutch Shell upgraded to Neutral from Sell at Redburn
05/04/20 UBS
Royal Dutch Shell price target lowered to 1,700 GBp from 1,800 GBp at UBS
05/01/20 Citi
Citi cuts Royal Dutch Shell price target 11% to GBp 1180
RDS.B Royal Dutch Shell
$30.54 /

-0.785 (-2.51%)

06/04/20 RBC Capital
Royal Dutch Shell price target raised to 2,000 GBp from 1,800 GBp at RBC Capital
05/04/20 UBS
Royal Dutch Shell price target lowered to 1,700 GBp from 1,800 GBp at UBS
04/21/20 JPMorgan
Royal Dutch Shell price target lowered to 1,650 GBp from 1,750 GBp at JPMorgan
LULU Lululemon
$311.96 /

+18.51 (+6.31%)

06/30/20 Morgan Stanley
Lululemon boosted competitive advantage with Mirror deal, says Morgan Stanley
06/30/20 MKM Partners
Lululemon's Mirror deal 'highly attractive and synergistic', says MKM Partners
06/30/20 Roth Capital
Roth boosts Peloton target to $66, says buy Mirror acquisition selloff
06/30/20 Piper Sandler
Piper Sandler favors Lululemon acquisition of Mirror
UBER Uber
$31.07 /

+1.435 (+4.84%)

07/01/20 BTIG
Uber consensus likely aggressive, says BTIG
06/30/20 SunTrust
Uber shouldn't face regulatory issues if it buys Postmates, says Suntrust
06/25/20 Deutsche Bank
Yandex interest in Uber's minority stake modest positive, says Deutsche Bank
06/16/20 JPMorgan
JPMorgan continues to prefer Facebook, Snap in online advertising
EADSY Airbus
$0.00 /

+ (+0.00%)

06/26/20 Bernstein
Airbus downgraded to Market Perform from Outperform at Bernstein
06/11/20 Credit Suisse
Hexcel price target raised to $52 from $34 at Credit Suisse
06/08/20 Goldman Sachs
Boeing price target raised to $238 from $209 at Goldman Sachs
05/07/20 Barclays
Airbus price target lowered to EUR 68 from EUR 69 at Barclays
TNDM TNDM
/

+

06/30/20 Stifel
Tandem Diabetes target raised to $80 after UnitedHealth coverage news at Stifel
06/30/20 Oppenheimer
UnitedHealth to start covering Tandem insulin pump, says Oppenheimer
06/30/20 Piper Sandler
United Health coverage a 'clear positive' for Tandem, says Piper Sandler
06/22/20 Oppenheimer
Tandem Diabetes price target raised to $102 from $92 at Oppenheimer
UNH UnitedHealth
$294.79 /

+5.49 (+1.90%)

07/01/20 SVB Leerink
UnitedHealth reinstated with an Outperform at SVB Leerink
AYI Acuity Brands
$95.47 /

+6.24 (+6.99%)

07/01/20 Credit Suisse
Acuity Brands price target raised to $115 from $109 at Credit Suisse
06/16/20
Fly Intel: Top five analyst downgrades
06/15/20 Goldman Sachs
Acuity Brands downgraded to Sell from Neutral at Goldman Sachs
06/09/20 JMP Securities
Acuity Brands downgraded to Market Perform from Outperform at JMP Securities
LQDA Liquidia Technologies
$8.36 /

-2.32 (-21.72%)

04/08/20 Wedbush
Liquidia Technologies price target raised to $41 from $37 at Wedbush
01/27/20 Wedbush
Liquidia NDA acceptance reduces regulatory risk, says Wedbush
12/26/19 Wedbush
Liquidia Technologies price target lowered to $37 from $50 at Wedbush
INO Inovio
$26.88 /

-4.83 (-15.23%)

07/01/20 Maxim
Inovio downgraded to Hold from Buy at Maxim
07/01/20 Roth Capital
Roth 'unimpressed' with Inovio data, downgrades to Sell with $11 target
07/01/20 Maxim
Inovio downgraded to Hold from Buy at Maxim
06/30/20 RBC Capital
RBC keeps Sector Perform on Inovio following 'positive' COVID-19 vaccine update
WFC Wells Fargo
$25.57 /

-0.13 (-0.51%)

UNH UnitedHealth
$294.79 /

+5.49 (+1.90%)

UBER Uber
$31.07 /

+1.435 (+4.84%)

TNDM TNDM
/

+

RDS.A Royal Dutch Shell
$32.70 /

-0.73 (-2.18%)

MU Micron
$51.50 /

+2.38 (+4.85%)

LULU Lululemon
$311.96 /

+18.51 (+6.31%)

LQDA Liquidia Technologies
$8.36 /

-2.32 (-21.72%)

INO Inovio
$26.88 /

-4.83 (-15.23%)

EADSY Airbus
$0.00 /

+ (+0.00%)

AYI Acuity Brands
$95.47 /

+6.24 (+6.99%)

  • 30
    Jun
  • 11
    Feb
  • 24
    Dec
  • 13
    Dec
  • 07
    Nov
  • 06
    Nov
WFC Wells Fargo
$25.57 /

-0.13 (-0.51%)

UNH UnitedHealth
$294.79 /

+5.49 (+1.90%)

UBER Uber
$31.07 /

+1.435 (+4.84%)

RDS.B Royal Dutch Shell
$30.54 /

-0.785 (-2.51%)

RDS.A Royal Dutch Shell
$32.70 /

-0.73 (-2.18%)

MU Micron
$51.50 /

+2.38 (+4.85%)

LULU Lululemon
$311.96 /

+18.51 (+6.31%)

INO Inovio
$26.88 /

-4.83 (-15.23%)

EADSY Airbus
$0.00 /

+ (+0.00%)

WFC Wells Fargo
$25.57 /

-0.13 (-0.51%)

UNH UnitedHealth
$294.79 /

+5.49 (+1.90%)

UBER Uber
$31.07 /

+1.435 (+4.84%)

TNDM TNDM
/

+

RDS.B Royal Dutch Shell
$30.54 /

-0.785 (-2.51%)

RDS.A Royal Dutch Shell
$32.70 /

-0.73 (-2.18%)

MU Micron
$51.50 /

+2.38 (+4.85%)

LULU Lululemon
$311.96 /

+18.51 (+6.31%)

LQDA Liquidia Technologies
$8.36 /

-2.32 (-21.72%)

INO Inovio
$26.88 /

-4.83 (-15.23%)

EADSY Airbus
$0.00 /

+ (+0.00%)

AYI Acuity Brands
$95.47 /

+6.24 (+6.99%)

WFC Wells Fargo
$25.57 /

-0.13 (-0.51%)

UNH UnitedHealth
$294.79 /

+5.49 (+1.90%)

UBER Uber
$31.07 /

+1.435 (+4.84%)

MU Micron
$51.50 /

+2.38 (+4.85%)

LULU Lululemon
$311.96 /

+18.51 (+6.31%)

LQDA Liquidia Technologies
$8.36 /

-2.32 (-21.72%)

INO Inovio
$26.88 /

-4.83 (-15.23%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:20
06/30/20
06/30
12:20
06/30/20
12:20
MU

Micron

$52.00 /

+2.88 (+5.86%)

, WFC

Wells Fargo

$25.71 /

+0.01 (+0.04%)

, UBER

Uber

$31.08 /

+1.445 (+4.88%)

, GRUB

GrubHub

$69.01 /

-0.66 (-0.95%)

, LULU

Lululemon

$312.61 /

+19.16 (+6.53%)

, PTON

Peloton

$58.33 /

+1.22 (+2.14%)

, RDS.A

Royal Dutch Shell

$32.34 /

-1.09 (-3.26%)

, BE

Bloom Energy

$10.75 /

+2.515 (+30.54%)

, AYI

Acuity Brands

$96.47 /

+7.24 (+8.11%)

, LQDA

Liquidia Technologies

$8.30 /

-2.38 (-22.28%)

, ERII

Energy Recovery

$7.74 /

-1.14 (-12.84%)

, SLB

Schlumberger

$18.12 /

+0.1 (+0.55%)

Stocks are higher at…

Open Full Text

ShowHide Related Items >><<
WFC Wells Fargo
$25.71 /

+0.01 (+0.04%)

UBER Uber
$31.08 /

+1.445 (+4.88%)

SLB Schlumberger
$18.12 /

+0.1 (+0.55%)

RDS.A Royal Dutch Shell
$32.34 /

-1.09 (-3.26%)

PTON Peloton
$58.33 /

+1.22 (+2.14%)

MU Micron
$52.00 /

+2.88 (+5.86%)

LULU Lululemon
$312.61 /

+19.16 (+6.53%)

LQDA Liquidia Technologies
$8.30 /

-2.38 (-22.28%)

GRUB GrubHub
$69.01 /

-0.66 (-0.95%)

ERII Energy Recovery
$7.74 /

-1.14 (-12.84%)

BE Bloom Energy
$10.75 /

+2.515 (+30.54%)

AYI Acuity Brands
$96.47 /

+7.24 (+8.11%)

MU Micron
$52.00 /

+2.88 (+5.86%)

06/30/20 RBC Capital
Micron price target raised to $60 from $55 at RBC Capital
06/30/20 Morgan Stanley
Morgan Stanley would add to Micron positions on weakness in coming 'rough patch'
06/30/20 Raymond James
Micron price target raised to $65 from $60 at Raymond James
06/30/20 Mizuho
Micron price target raised to $63 from $60 at Mizuho
WFC Wells Fargo
$25.71 /

+0.01 (+0.04%)

06/30/20 JPMorgan
Wells Fargo needs to cut dividend 'much more' than 25%, says JPMorgan
06/30/20 RBC Capital
Wells Fargo price target lowered to $29 from $35 at RBC Capital
06/26/20 Morgan Stanley
Morgan Stanley sees dividend cuts at Wells Fargo, Capital One after stress tests
06/11/20 JPMorgan
Wells Fargo dividend very likely to be cut, says JPMorgan
UBER Uber
$31.08 /

+1.445 (+4.88%)

06/30/20 SunTrust
Uber shouldn't face regulatory issues if it buys Postmates, says Suntrust
06/25/20 Deutsche Bank
Yandex interest in Uber's minority stake modest positive, says Deutsche Bank
06/16/20 JPMorgan
JPMorgan continues to prefer Facebook, Snap in online advertising
06/15/20 B. Riley FBR
B. Riley FBR upgrades James River to Buy, sees takeout potential
GRUB GrubHub
$69.01 /

-0.66 (-0.95%)

06/25/20 Canaccord
Canaccord downgraded GrubHub after announced merger
06/25/20 Canaccord
GrubHub downgraded to Hold from Buy at Canaccord
06/12/20 DA Davidson
GrubHub upgraded to Neutral from Underperform at DA Davidson
LULU Lululemon
$312.61 /

+19.16 (+6.53%)

06/30/20 Morgan Stanley
Lululemon boosted competitive advantage with Mirror deal, says Morgan Stanley
06/30/20 MKM Partners
Lululemon's Mirror deal 'highly attractive and synergistic', says MKM Partners
06/30/20 Roth Capital
Roth boosts Peloton target to $66, says buy Mirror acquisition selloff
06/30/20 Piper Sandler
Piper Sandler favors Lululemon acquisition of Mirror
PTON Peloton
$58.33 /

+1.22 (+2.14%)

06/26/20 Needham
Peloton price target raised to $65 from $50 at Needham
06/25/20 Raymond James
Peloton resumed with an Outperform at Raymond James
06/24/20 KeyBanc
Peloton price target raised to $70 from $55 at KeyBanc
RDS.A Royal Dutch Shell
$32.34 /

-1.09 (-3.26%)

06/15/20 UBS
Royal Dutch Shell price target raised to 1,750 GBp from 1,650 GBp at UBS
05/13/20 Redburn
Royal Dutch Shell upgraded to Neutral from Sell at Redburn
05/04/20 UBS
Royal Dutch Shell price target lowered to 1,700 GBp from 1,800 GBp at UBS
05/01/20 Citi
Citi cuts Royal Dutch Shell price target 11% to GBp 1180
BE Bloom Energy
$10.75 /

+2.515 (+30.54%)

05/28/20 JPMorgan
Bloom Energy price target raised to $17 from $14 at JPMorgan
05/12/20 Morgan Stanley
Bloom Energy's underlying demand still appears strong, says Morgan Stanley
04/24/20 Morgan Stanley
Federal support for renewables could come in summer, says Morgan Stanley
03/09/20 JPMorgan
Solar stocks providing 'unanticipated safe haven,' says JPMorgan
AYI Acuity Brands
$96.47 /

+7.24 (+8.11%)

06/16/20
Fly Intel: Top five analyst downgrades
06/15/20 Goldman Sachs
Acuity Brands downgraded to Sell from Neutral at Goldman Sachs
06/09/20 JMP Securities
Acuity Brands downgraded to Market Perform from Outperform at JMP Securities
06/08/20 Oppenheimer
Acuity Brands upgraded to Outperform at Oppenheimer
LQDA Liquidia Technologies
$8.30 /

-2.38 (-22.28%)

04/08/20 Wedbush
Liquidia Technologies price target raised to $41 from $37 at Wedbush
01/27/20 Wedbush
Liquidia NDA acceptance reduces regulatory risk, says Wedbush
12/26/19 Wedbush
Liquidia Technologies price target lowered to $37 from $50 at Wedbush
ERII Energy Recovery
$7.74 /

-1.14 (-12.84%)

06/30/20
Fly Intel: Top five analyst downgrades
06/30/20 B. Riley FBR
B. Riley FBR downgrades Energy Recovery on Schlumberger deal exit
06/30/20 B. Riley FBR
Energy Recovery downgraded to Neutral from Buy at B. Riley FBR
03/09/20 Evercore ISI
Energy Recovery downgraded to In Line from Outperform at Evercore ISI
SLB Schlumberger
$18.12 /

+0.1 (+0.55%)

06/24/20 HSBC
Schlumberger price target raised to $18.10 from $17.10 at HSBC
06/18/20 JPMorgan
Schlumberger price target raised to $17 from $16 at JPMorgan
06/04/20 Cowen
Schlumberger could have bottomed in Q2, says Cowen
WFC Wells Fargo
$25.71 /

+0.01 (+0.04%)

UBER Uber
$31.08 /

+1.445 (+4.88%)

SLB Schlumberger
$18.12 /

+0.1 (+0.55%)

RDS.A Royal Dutch Shell
$32.34 /

-1.09 (-3.26%)

PTON Peloton
$58.33 /

+1.22 (+2.14%)

MU Micron
$52.00 /

+2.88 (+5.86%)

LULU Lululemon
$312.61 /

+19.16 (+6.53%)

LQDA Liquidia Technologies
$8.30 /

-2.38 (-22.28%)

GRUB GrubHub
$69.01 /

-0.66 (-0.95%)

ERII Energy Recovery
$7.74 /

-1.14 (-12.84%)

BE Bloom Energy
$10.75 /

+2.515 (+30.54%)

AYI Acuity Brands
$96.47 /

+7.24 (+8.11%)

  • 30
    Jun
  • 12
    May
  • 11
    Feb
  • 24
    Dec
  • 13
    Dec
  • 07
    Nov
  • 06
    Nov
  • 26
    Sep
WFC Wells Fargo
$25.71 /

+0.01 (+0.04%)

UBER Uber
$31.08 /

+1.445 (+4.88%)

SLB Schlumberger
$18.12 /

+0.1 (+0.55%)

RDS.A Royal Dutch Shell
$32.34 /

-1.09 (-3.26%)

PTON Peloton
$58.33 /

+1.22 (+2.14%)

MU Micron
$52.00 /

+2.88 (+5.86%)

LULU Lululemon
$312.61 /

+19.16 (+6.53%)

GRUB GrubHub
$69.01 /

-0.66 (-0.95%)

BE Bloom Energy
$10.75 /

+2.515 (+30.54%)

WFC Wells Fargo
$25.71 /

+0.01 (+0.04%)

UBER Uber
$31.08 /

+1.445 (+4.88%)

SLB Schlumberger
$18.12 /

+0.1 (+0.55%)

RDS.A Royal Dutch Shell
$32.34 /

-1.09 (-3.26%)

PTON Peloton
$58.33 /

+1.22 (+2.14%)

MU Micron
$52.00 /

+2.88 (+5.86%)

LULU Lululemon
$312.61 /

+19.16 (+6.53%)

LQDA Liquidia Technologies
$8.30 /

-2.38 (-22.28%)

GRUB GrubHub
$69.01 /

-0.66 (-0.95%)

BE Bloom Energy
$10.75 /

+2.515 (+30.54%)

AYI Acuity Brands
$96.47 /

+7.24 (+8.11%)

WFC Wells Fargo
$25.71 /

+0.01 (+0.04%)

UBER Uber
$31.08 /

+1.445 (+4.88%)

SLB Schlumberger
$18.12 /

+0.1 (+0.55%)

PTON Peloton
$58.33 /

+1.22 (+2.14%)

MU Micron
$52.00 /

+2.88 (+5.86%)

LULU Lululemon
$312.61 /

+19.16 (+6.53%)

LQDA Liquidia Technologies
$8.30 /

-2.38 (-22.28%)

GRUB GrubHub
$69.01 /

-0.66 (-0.95%)

BE Bloom Energy
$10.75 /

+2.515 (+30.54%)

Syndicate
Liquidia Technologies 9.375M share Spot Secondary priced at $8.00 » 23:02
06/29/20
06/29
23:02
06/29/20
23:02
LQDA

Liquidia Technologies

$10.68 /

-0.27 (-2.47%)

Jefferies acted as lead…

Jefferies acted as lead book running manager for the offering.

ShowHide Related Items >><<
LQDA Liquidia Technologies
$10.68 /

-0.27 (-2.47%)

LQDA Liquidia Technologies
$10.68 /

-0.27 (-2.47%)

04/08/20 Wedbush
Liquidia Technologies price target raised to $41 from $37 at Wedbush
01/27/20 Wedbush
Liquidia NDA acceptance reduces regulatory risk, says Wedbush
12/26/19 Wedbush
Liquidia Technologies price target lowered to $37 from $50 at Wedbush
LQDA Liquidia Technologies
$10.68 /

-0.27 (-2.47%)

  • 30
    Jun
  • 24
    Dec
LQDA Liquidia Technologies
$10.68 /

-0.27 (-2.47%)

LQDA Liquidia Technologies
$10.68 /

-0.27 (-2.47%)

Syndicate
Liquidia announces common stock offering, no amount given » 16:19
06/29/20
06/29
16:19
06/29/20
16:19
LQDA

Liquidia Technologies

$10.68 /

-0.27 (-2.47%)

Liquidia Technologies…

Liquidia Technologies announced that it has commenced an underwritten public offering of its common stock. Jefferies is acting as the sole book-running manager for the proposed offering. Needham & Company and Wedbush PacGrow are acting as co-managers.

ShowHide Related Items >><<
LQDA Liquidia Technologies
$10.68 /

-0.27 (-2.47%)

LQDA Liquidia Technologies
$10.68 /

-0.27 (-2.47%)

04/08/20 Wedbush
Liquidia Technologies price target raised to $41 from $37 at Wedbush
01/27/20 Wedbush
Liquidia NDA acceptance reduces regulatory risk, says Wedbush
12/26/19 Wedbush
Liquidia Technologies price target lowered to $37 from $50 at Wedbush
LQDA Liquidia Technologies
$10.68 /

-0.27 (-2.47%)

  • 24
    Dec
LQDA Liquidia Technologies
$10.68 /

-0.27 (-2.47%)

LQDA Liquidia Technologies
$10.68 /

-0.27 (-2.47%)

Hot Stocks
Liquidia to acquire RareGen and expand presence in PAH » 16:04
06/29/20
06/29
16:04
06/29/20
16:04
LQDA

Liquidia Technologies

$10.56 /

-0.39 (-3.56%)

Liquidia Technologies…

Liquidia Technologies announced it has entered into a definitive agreement to acquire RareGen,, a portfolio company of PBM Capital, through an all-stock merger. Liquidia and RareGen will consolidate under a new holding company, to be named Liquidia Corporation, which is expected to trade on the Nasdaq Capital Market under the ticker symbol "LQDA," as the successor to Liquidia Technologies. RareGen provides strategy, investment, and commercialization for rare disease pharmaceutical products. RareGen has a small, targeted sales force focused on PAH. RareGen acquired the right to promote Sandoz's first-to-file generic of Remodulin for the treatment of patients with PAH. In March 2019, Sandoz and RareGen launched their generic treprostinil injection, making it the first generic of Remodulin to market. Liquidia Corporation will assume RareGen's responsibilities under the agreement with Sandoz following closing of the merger transaction. This acquisition reinforces Liquidia's commitment to the PAH community and continued pursuit to address the unmet needs of patients and the healthcare professionals who treat them. The potential introduction of LIQ861 as a more convenient inhaled treprostinil over the currently available inhaled option, combined with RareGen's parenteral treprostinil option emphasize Liquidia's commitment to addressing the patient continuum of treatment. In addition, these combined entities further enhance the organization's knowledge base, customer reach and commercial planning in preparation for the potential launch of LIQ861, if approved.

ShowHide Related Items >><<
LQDA Liquidia Technologies
$10.56 /

-0.39 (-3.56%)

LQDA Liquidia Technologies
$10.56 /

-0.39 (-3.56%)

04/08/20 Wedbush
Liquidia Technologies price target raised to $41 from $37 at Wedbush
01/27/20 Wedbush
Liquidia NDA acceptance reduces regulatory risk, says Wedbush
12/26/19 Wedbush
Liquidia Technologies price target lowered to $37 from $50 at Wedbush
LQDA Liquidia Technologies
$10.56 /

-0.39 (-3.56%)

  • 24
    Dec
LQDA Liquidia Technologies
$10.56 /

-0.39 (-3.56%)

LQDA Liquidia Technologies
$10.56 /

-0.39 (-3.56%)

Over a month ago
Hot Stocks
Liquidia to 'vigorously defend' against United Therapeutics patent suit » 15:34
06/05/20
06/05
15:34
06/05/20
15:34
LQDA

Liquidia Technologies

$7.50 /

-1.98 (-20.89%)

, UTHR

United Therapeutics

$124.00 /

+1.695 (+1.39%)

Liquidia Technologies…

Liquidia Technologies (LQDA) announced that United Therapeutics (UTHR) filed a patent infringement action under the Hatch-Waxman Act against the company in the U.S. District Court for the District of Delaware asserting infringement of U.S. Patent Nos. 9,604,901 and 9,593,066 relating to UTC's Tyvaso, a nebulized treprostinil solution for the treatment of pulmonary arterial hypertension, or PAH. This lawsuit is in response to the New Drug Application the company filed with the U.S. Food and Drug Administration requesting approval to market LIQ861, a dry powder inhalation of treprostinil for the treatment of PAH. The LIQ861 NDA was filed under the 505(b)(2) regulatory pathway with Tyvaso as the reference listed drug. Under the Hatch-Waxman Act, the FDA is automatically precluded from approving the LIQ861 NDA for up to 30 months or until resolution of the lawsuit, absent an earlier judgment unfavorable to UTC by the court. "We believe these patents to be invalid and/or not infringed by the practice of LIQ861 and we will vigorously defend the suit and our freedom to pursue the commercialization of LIQ861. We are acutely aware of the need that exists among PAH patients to have access to treatments beyond those which are currently available and are dedicated to addressing that need in the most expedient way possible," stated Neal Fowler, CEO at Liquidia.

ShowHide Related Items >><<
UTHR United Therapeutics
$124.00 /

+1.695 (+1.39%)

LQDA Liquidia Technologies
$7.50 /

-1.98 (-20.89%)

LQDA Liquidia Technologies
$7.50 /

-1.98 (-20.89%)

04/08/20 Wedbush
Liquidia Technologies price target raised to $41 from $37 at Wedbush
01/27/20 Wedbush
Liquidia NDA acceptance reduces regulatory risk, says Wedbush
12/26/19 Wedbush
Liquidia Technologies price target lowered to $37 from $50 at Wedbush
UTHR United Therapeutics
$124.00 /

+1.695 (+1.39%)

04/07/20
United Therapeutics participates in a conference with JPMorgan
03/10/20
Fly Intel: Top five analyst upgrades
03/10/20 Jefferies
Jefferies upgrades United Therapeutics on potential for Remodulin growth
UTHR United Therapeutics
$124.00 /

+1.695 (+1.39%)

LQDA Liquidia Technologies
$7.50 /

-1.98 (-20.89%)

UTHR United Therapeutics
$124.00 /

+1.695 (+1.39%)

UTHR United Therapeutics
$124.00 /

+1.695 (+1.39%)

LQDA Liquidia Technologies
$7.50 /

-1.98 (-20.89%)

LQDA Liquidia Technologies
$7.50 /

-1.98 (-20.89%)

Hot Stocks
Liquidia drops after United Therapeutics files patent infringement lawsuit » 10:38
06/05/20
06/05
10:38
06/05/20
10:38
LQDA

Liquidia Technologies

$7.85 /

-1.63 (-17.19%)

, UTHR

United Therapeutics

$122.25 /

-0.055 (-0.04%)

Shares of Liquidia…

Shares of Liquidia Technologies (LQDA) fell on Friday morning after United Therapeutics (UTHR) filed a lawsuit in the U.S. District Court for the District of Delaware for infringement of patents related to United Therapeutics' Tyvaso. United Therapeutics said in a statement earlier that the lawsuit is based on a New Drug Application filed by Liquidia with the U.S. Food and Drug Administration requesting approval to market LIQ861, a dry powder inhalation formulation of treprostinil. In April, United Therapeutics said it received a Paragraph IV notification letter from Liquidia indicating that Liquidia's NDA contains a certification alleging that LIQ861 will not infringe any of the patents then listed in the Orange Book for Tyvaso because those patents are not valid, not enforceable, and/or will not be infringed by the commercial manufacture, use, or sale of LIQ861. United Therapeutics said it filed its lawsuit within 45 days of receipt of notice from Liquidia of its NDA filing, and that as a result, under the Hatch-Waxman Act, the FDA is automatically precluded from approving Liquidia's NDA for up to 30 months or until the resolution of the litigation, whichever occurs first. United Therapeutics said it intends to "vigorously enforce its intellectual property rights relating to Tyvaso." Shares of Liquidia are down 17.2% to $7.83, while United Therapeutics shares are fractionally higher at $122.59.

ShowHide Related Items >><<
UTHR United Therapeutics
$122.25 /

-0.055 (-0.04%)

LQDA Liquidia Technologies
$7.85 /

-1.63 (-17.19%)

LQDA Liquidia Technologies
$7.85 /

-1.63 (-17.19%)

04/08/20 Wedbush
Liquidia Technologies price target raised to $41 from $37 at Wedbush
01/27/20 Wedbush
Liquidia NDA acceptance reduces regulatory risk, says Wedbush
12/26/19 Wedbush
Liquidia Technologies price target lowered to $37 from $50 at Wedbush
UTHR United Therapeutics
$122.25 /

-0.055 (-0.04%)

04/07/20
United Therapeutics participates in a conference with JPMorgan
03/10/20
Fly Intel: Top five analyst upgrades
03/10/20 Jefferies
Jefferies upgrades United Therapeutics on potential for Remodulin growth
UTHR United Therapeutics
$122.25 /

-0.055 (-0.04%)

LQDA Liquidia Technologies
$7.85 /

-1.63 (-17.19%)

UTHR United Therapeutics
$122.25 /

-0.055 (-0.04%)

UTHR United Therapeutics
$122.25 /

-0.055 (-0.04%)

LQDA Liquidia Technologies
$7.85 /

-1.63 (-17.19%)

LQDA Liquidia Technologies
$7.85 /

-1.63 (-17.19%)

Options
Thirteen new option listings and four option delistings on May 28th » 08:30
05/28/20
05/28
08:30
05/28/20
08:30
CFRX

ContraFect

$5.35 /

-0.045 (-0.83%)

, FREQ

Frequency Therapeutics

$18.27 /

+0.8 (+4.58%)

, HARP

Harpoon Therapeutics

$21.77 /

-3.23 (-12.92%)

, HOOK

Hookipa Pharma

$11.23 /

+0.73 (+6.95%)

, HSTO

Histogen

$4.61 /

+4.054 (+729.14%)

, IFRX

InflaRx

$8.36 /

+0.2 (+2.45%)

, KNSA

Kiniksa

$20.86 /

-0.89 (-4.09%)

, KZR

Kezar Life Sciences

$5.30 /

+0.05 (+0.95%)

, LQDA

Liquidia Technologies

$9.03 /

+0.05 (+0.56%)

, OVID

Ovid Therapeutics

$5.71 /

-0.97 (-14.52%)

, PRVL

Prevail Therapeutics

$16.83 /

-0.38 (-2.21%)

, CNAT

Conatus

$0.00 /

+ (+0.00%)

, CORV

Correvio

$0.42 /

+ (+0.00%)

, CTRC

Centric Brands

$0.19 /

-0.0279 (-12.65%)

, UNT

Unit Corp.

/

+

New option listings for…

New option listings for May 28th include ContraFect (CFRX), Centric Brands Inc (CTRCQ), Frequency Therapeutics Inc (FREQ), Harpoon Therapeutics Inc (HARP), HOOKIPA Pharma Inc (HOOK), Histogen Inc (HSTO), InflaRx NV (IFRX), Kiniksa Pharmaceuticals Ltd (Class A Stock) (KNSA), Kezar Life Sciences Inc (KZR), Liquidia Technologies Inc (LQDA), Ovid Therapeutics (OVID), Prevail Therapeutics Inc (PRVL), and Unit Corp (UNTCQ). Option delistings effective May 28th include Conatus Pharmaceuticals Inc (CNAT), Correvio Pharma Corporation (CORV), Centric Brands Inc (CTRC), and Unit Corp (UNT).

ShowHide Related Items >><<
UNT Unit Corp.
/

+

PRVL Prevail Therapeutics
$16.83 /

-0.38 (-2.21%)

OVID Ovid Therapeutics
$5.71 /

-0.97 (-14.52%)

LQDA Liquidia Technologies
$9.03 /

+0.05 (+0.56%)

KZR Kezar Life Sciences
$5.30 /

+0.05 (+0.95%)

KNSA Kiniksa
$20.86 /

-0.89 (-4.09%)

IFRX InflaRx
$8.36 /

+0.2 (+2.45%)

HSTO Histogen
$4.61 /

+4.054 (+729.14%)

HOOK Hookipa Pharma
$11.23 /

+0.73 (+6.95%)

HARP Harpoon Therapeutics
$21.77 /

-3.23 (-12.92%)

FREQ Frequency Therapeutics
$18.27 /

+0.8 (+4.58%)

CTRC Centric Brands
$0.19 /

-0.0279 (-12.65%)

CORV Correvio
$0.42 /

+ (+0.00%)

CNAT Conatus
$0.00 /

+ (+0.00%)

CFRX ContraFect
$5.35 /

-0.045 (-0.83%)

CFRX ContraFect
$5.35 /

-0.045 (-0.83%)

10/02/19 Piper Sandler
Piper says design differentiates ContraFect trial from other antibiotic studies
06/11/19 Maxim
ContraFect initiated with a Buy at Maxim
FREQ Frequency Therapeutics
$18.27 /

+0.8 (+4.58%)

05/18/20 JPMorgan
JPMorgan downgrades Frequency Therapeutics on unclear data timelines
05/18/20 JPMorgan
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan
10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
10/28/19 Cowen
Frequency Therapeutics initiated with an Outperform at Cowen
HARP Harpoon Therapeutics
$21.77 /

-3.23 (-12.92%)

05/22/20 Piper Sandler
Harpoon Therapeutics initiated with an Overweight at Piper Sandler
04/16/20 Citi
Citi opens 'positive 90-day catalyst watch' on Harpoon Therapeutics
02/28/20
Fly Intel: Top five analyst initiations
02/27/20 SunTrust
Harpoon Therapeutics initiated with a Buy at SunTrust
HOOK Hookipa Pharma
$11.23 /

+0.73 (+6.95%)

09/27/19 H.C. Wainwright
Hookipa Pharma initiated with a Buy at H.C. Wainwright
HSTO Histogen
$4.61 /

+4.054 (+729.14%)

IFRX InflaRx
$8.36 /

+0.2 (+2.45%)

05/21/20 BMO Capital
InflaRx price target raised to $7 from $4 at BMO Capital
05/21/20 Raymond James
Raymond James doubles InflaRx price target to $20 ahead of COVID data
05/21/20 Raymond James
InflaRx price target raised to $20 from $10 at Raymond James
04/30/20 Raymond James
InflaRx upgraded to Outperform from Market Perform at Raymond James
KNSA Kiniksa
$20.86 /

-0.89 (-4.09%)

04/01/20
Fly Intel: Top five analyst initiations
04/01/20 BofA
Kiniksa initiated with a Buy at BofA
12/06/19 Goldman Sachs
Kiniksa assumed to Buy from Neutral at Goldman Sachs
08/14/19 JMP Securities
Kiniksa price target lowered to $35 from $44 at JMP Securities
KZR Kezar Life Sciences
$5.30 /

+0.05 (+0.95%)

05/05/20 H.C. Wainwright
Kezar Life Sciences price target lowered to $9 from $15 at H.C. Wainwright
07/29/19 H.C. Wainwright
Kezar Life Sciences initiated with a Buy at H.C. Wainwright
LQDA Liquidia Technologies
$9.03 /

+0.05 (+0.56%)

04/08/20 Wedbush
Liquidia Technologies price target raised to $41 from $37 at Wedbush
01/27/20 Wedbush
Liquidia NDA acceptance reduces regulatory risk, says Wedbush
12/26/19 Wedbush
Liquidia Technologies price target lowered to $37 from $50 at Wedbush
OVID Ovid Therapeutics
$5.71 /

-0.97 (-14.52%)

05/22/20 Cantor Fitzgerald
Zynerba price target raised to $21 from $12 at Cantor Fitzgerald
05/07/20 Piper Sandler
Ovid's gaboxadol data in Fragile X 'promising,' says Piper Sandler
03/30/20 Piper Sandler
Piper says Ovid data suggests potential use for soticlestat in CDD/Dup15q
09/24/19 Citi
Ovid Therapeutics price target raised to $10 from $8 at Citi
PRVL Prevail Therapeutics
$16.83 /

-0.38 (-2.21%)

05/14/20 Piper Sandler
Prevail's 'quiet' Q1 report 'a victory in this environment,' says Piper Sandler
04/27/20 Piper Sandler
Prevail 20% pullback brings 'unique' buying opportunity, says Piper Sandler
04/09/20
Fly Intel: Top five analyst initiations
04/09/20 Piper Sandler
Prevail Therapeutics initiated with an Overweight at Piper Sandler
CNAT Conatus
$0.00 /

+ (+0.00%)

CORV Correvio
$0.42 /

+ (+0.00%)

12/11/19 H.C. Wainwright
Correvio downgraded to Neutral from Buy at H.C. Wainwright
09/03/19 Cantor Fitzgerald
Correvio initiated with an Overweight at Cantor Fitzgerald
CTRC Centric Brands
$0.19 /

-0.0279 (-12.65%)

UNT Unit Corp.
/

+

03/20/20 Stephens
Stephens upgrades Hess, downgrades 11 others in E&P following oil's melt down
03/20/20 Stephens
Unit Corp. downgraded to Underweight from Equal Weight at Stephens
01/06/20 Raymond James
Unit Corp. downgraded at Raymond James on commodity price weakness
01/06/20 Raymond James
Unit Corp. downgraded to Underperform from Market Perform at Raymond James
UNT Unit Corp.
/

+

PRVL Prevail Therapeutics
$16.83 /

-0.38 (-2.21%)

OVID Ovid Therapeutics
$5.71 /

-0.97 (-14.52%)

LQDA Liquidia Technologies
$9.03 /

+0.05 (+0.56%)

KZR Kezar Life Sciences
$5.30 /

+0.05 (+0.95%)

KNSA Kiniksa
$20.86 /

-0.89 (-4.09%)

IFRX InflaRx
$8.36 /

+0.2 (+2.45%)

HOOK Hookipa Pharma
$11.23 /

+0.73 (+6.95%)

HARP Harpoon Therapeutics
$21.77 /

-3.23 (-12.92%)

FREQ Frequency Therapeutics
$18.27 /

+0.8 (+4.58%)

CFRX ContraFect
$5.35 /

-0.045 (-0.83%)

CORV Correvio
$0.42 /

+ (+0.00%)

LQDA Liquidia Technologies
$9.03 /

+0.05 (+0.56%)

KZR Kezar Life Sciences
$5.30 /

+0.05 (+0.95%)

KNSA Kiniksa
$20.86 /

-0.89 (-4.09%)

IFRX InflaRx
$8.36 /

+0.2 (+2.45%)

HARP Harpoon Therapeutics
$21.77 /

-3.23 (-12.92%)

CTRC Centric Brands
$0.19 /

-0.0279 (-12.65%)

CFRX ContraFect
$5.35 /

-0.045 (-0.83%)

CORV Correvio
$0.42 /

+ (+0.00%)

Hot Stocks
Liquidia Technologies appoints Tushar Shah as CMO » 07:17
05/18/20
05/18
07:17
05/18/20
07:17
LQDA

Liquidia Technologies

$7.31 /

-0.21 (-2.79%)

, TEVA

Teva

$11.21 /

+0.25 (+2.28%)

Liquidia Technologies…

Liquidia Technologies (LQDA) announced the appointment of Tushar Shah, M.D., to the newly created position of chief medical officer. In this role, Dr. Shah will oversee all aspects of research, clinical development, medical affairs, and regulatory affairs for Liquidia.Dr. Shah joins Liquidia from Teva Pharmaceuticals (TEVA), where he served as Head of Global Specialty Clinical Development with oversight of all phases of clinical development across all therapeutic areas including CNS, immunology, respiratory, oncology and biosimilars.

ShowHide Related Items >><<
TEVA Teva
$11.21 /

+0.25 (+2.28%)

LQDA Liquidia Technologies
$7.31 /

-0.21 (-2.79%)

LQDA Liquidia Technologies
$7.31 /

-0.21 (-2.79%)

04/08/20 Wedbush
Liquidia Technologies price target raised to $41 from $37 at Wedbush
01/27/20 Wedbush
Liquidia NDA acceptance reduces regulatory risk, says Wedbush
12/26/19 Wedbush
Liquidia Technologies price target lowered to $37 from $50 at Wedbush
TEVA Teva
$11.21 /

+0.25 (+2.28%)

05/11/20 UBS
Teva price target raised to ILS 15 from ILS 12 at UBS
04/24/20
Fly Intel: Top five analyst initiations
04/24/20 Citi
Teva initiated with a Neutral at Citi
04/06/20 UBS
Teva upgraded to Buy from Neutral at UBS
TEVA Teva
$11.21 /

+0.25 (+2.28%)

LQDA Liquidia Technologies
$7.31 /

-0.21 (-2.79%)

TEVA Teva
$11.21 /

+0.25 (+2.28%)

TEVA Teva
$11.21 /

+0.25 (+2.28%)

LQDA Liquidia Technologies
$7.31 /

-0.21 (-2.79%)

TEVA Teva
$11.21 /

+0.25 (+2.28%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.